In 43,810 statin initiators, the incidence rate for Parkinson disease (PD) was 1.68 and 3.52 per 1,000,000 person-days for lipophilic and hydrophilic statins, respectively. Continuation of lipophilic statins was associated with a decreased risk of PD compared with statin discontinuation. Lipophilic statins should be considered first in patients with dyslipidemia. 
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